Figure 3.
CAR T cells are effective for CD19-dim B-ALL, but there is a higher rate of failure to achieve MRD–remission and CD19–MRD/relapse in blinatumomab-pretreated patients. (A) Distribution of CD19 expression before CAR T-cell therapy in all patients (n = 166). (B) Proportion of remission and NR/CD19-negMRD/R among the CD19-normal/bright and CD19-dim B-ALL cases. (C) Distribution of CD19 expression among the patients previously treated with blinatumomab (blina group; n = 16). (D) Proportion of remission and NR/CD19− MRD/R among patients stratified by prior blinatumomab therapy. (E) Flow cytometric data from HP-12 at relapse (2 plots on the left) and postblinatumomab pre-CAR (2 plots on the right) time points show loss of CD19 expression after blinatumomab.

CAR T cells are effective for CD19-dim B-ALL, but there is a higher rate of failure to achieve MRD–remission and CD19–MRD/relapse in blinatumomab-pretreated patients. (A) Distribution of CD19 expression before CAR T-cell therapy in all patients (n = 166). (B) Proportion of remission and NR/CD19-negMRD/R among the CD19-normal/bright and CD19-dim B-ALL cases. (C) Distribution of CD19 expression among the patients previously treated with blinatumomab (blina group; n = 16). (D) Proportion of remission and NR/CD19− MRD/R among patients stratified by prior blinatumomab therapy. (E) Flow cytometric data from HP-12 at relapse (2 plots on the left) and postblinatumomab pre-CAR (2 plots on the right) time points show loss of CD19 expression after blinatumomab.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal